By Giulia Petroni 
 

Bayer AG said Thursday that it has agreed to collaborate with CureVac NV to support the development and supply of the U.S.-listed biopharmaceutical company's Covid-19 vaccine candidate CVnCoV.

Under the agreement, the German chemical and pharmaceutical conglomerate will support CureVac with country operations within the European Union and selected additional markets in order to facilitate the supply of several hundred million doses. CureVac will be the marketing authorization holder for the product.

The financial terms of the deal weren't disclosed.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

January 07, 2021 03:00 ET (08:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Bayer Charts.
Bayer (TG:BAYN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Bayer Charts.